EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy-Reference-Cited by-同舟云学术

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

Published:2012-04 Issue:4 Volume:7 Page:672-680
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Milella Michele,Nuzzo Carmen,Bria Emilio,Sperduti Isabella,Visca Paolo,Buttitta Fiamma,Antoniani Barbara,Merola Roberta,Gelibter Alain,Cuppone Federica,D'Alicandro Valerio,Ceribelli Anna,Rinaldi Massimo,Cianciulli Anna,Felicioni Lara,Malatesta Sara,Marchetti Antonio,Mottolese Marcella,Cognetti Francesco

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology;Kris;J Clin Oncol,2010

3. Multidisciplinary management of lung cancer;Spira;N Engl J Med,2004

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group;BMJ,1995

5. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer;Comis;Oncologist,2005

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer;Translational Oncology;2021-11

2. HER2 Aberrations in NSCLC: So Close Yet So Far;JCO Precision Oncology;2020-11

3. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis;Cancer Treatment and Research Communications;2020

4. Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?;Journal of Oncology;2019-05-23

5. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland;Diagnostic Pathology;2019-02-11